Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCEP.110.960237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Attention-deficit/hyperactivity disorder (ADHD) in adults: a multilayered approach to a serious disorder of inattention to the future.
Arq Neuropsiquiatr
July 2024
Pontifícia Universidade Católica do Rio Grande do Sul, Escola de Medicina, Núcleo de Neurociências, Porto Alegre RS, Brazil.
Attention-deficit/hyperactivity disorder (ADHD) affects people of all ages, yet its presentation varies as the person matures and social demands increase from childhood into adulthood. Interestingly, when analyzing the disorder in adults, it is not immediately clear what the 'attention deficit' in the ADHD denomination exactly means. Adults with ADHD have a broad range of difficulties, far beyond an attentional deficit, that impact negatively their social functioning and often lead to failures in all walks of life.
View Article and Find Full Text PDFReconciling the protean manifestations of arrhythmogenic cardiomyopathy.
Circ Arrhythm Electrophysiol
December 2010
DHCR7 mutation carrier rates and prevalence of the RSH/Smith-Lemli-Opitz syndrome: where are the patients?
Am J Med Genet A
October 2006
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.
RSH/Smith-Lemli-Opitz (SLOS) is an inborn error of metabolism with protean manifestations. Its exact incidence and prevalence are not known; however, the carrier rate for the most frequently occurring mutation, the null mutation IVS8-1G > C, is approximately 1 in 100 for the Caucasian population in North America (1%) and possibly as high as 1 in 50 to 1 in 30 in Central European populations (2-3.3%).
View Article and Find Full Text PDFInverse, protean, and ligand-selective agonism: matters of receptor conformation.
FASEB J
March 2001
Department of Receptor Biochemistry, Glaxo SmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA.
Concepts regarding the mechanisms by which drugs activate receptors to produce physiological response have progressed beyond considering the receptor as a simple on-off switch. Current evidence suggests that the idea that agonists produce only varying degrees of receptor activation is obsolete and must be reconciled with data to show that agonist efficacy has texture as well as magnitude. Thus, agonists can block system constitutive response (inverse agonists), behave as positive and inverse agonists on the same receptor (protean agonists), and differ in the stimulus pattern they produce in physiological systems (ligand-selective agonists).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!